Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer
暂无分享,去创建一个
Yasuo Ohashi | Junichi Sakamoto | Tomasz Burzykowski | Marc Buyse | Xavier Paoletti | Mitsuru Sasako | Stefan Michiels | Koji Oba | D. Sargent | M. Buyse | J. Pignon | E. Van Cutsem | S. Michiels | X. Paoletti | Y. Ohashi | J. Sakamoto | P. Rougier | T. Burzykowski | K. Oba | M. Sasako | Eric Van Cutsem | Philippe Rougier | Daniel Sargent | Jean-Pierre Pignon | A. Meta-analysis
[1] J. Ajani,et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] John P A Ioannidis,et al. Number of published systematic reviews and global burden of disease: database analysis , 2003, BMJ : British Medical Journal.
[3] F. Ciardiello,et al. Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] Douglas G Altman,et al. Interaction revisited: the difference between two estimates , 2003, BMJ : British Medical Journal.
[5] Karen Golden-Biddle,et al. Towards systematic reviews that inform health care management and policy-making , 2005, Journal of health services research & policy.
[6] H S Sacks,et al. Meta-analysis: an update. , 1996, The Mount Sinai journal of medicine, New York.
[7] H. Espejo,et al. [Gastric cancer]. , 1996, Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru.
[8] J. Tilburt,et al. Value judgments in the analysis and synthesis of evidence. , 2008, Journal of clinical epidemiology.
[9] D. Amadori,et al. A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. Dorgan,et al. Evaluating the quality of systematic reviews in the emergency medicine literature. , 2001, Annals of emergency medicine.
[11] Alex J. Sutton,et al. Evidence Concerning the Consequences of Publication and Related Biases , 2006 .
[12] P. Schlag,et al. Adjuvant 5-fluorouracil and BCNU chemotherapy in gastric cancer: 3-year results. , 1982, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[13] M. Puhan,et al. Comparative Effectiveness of Drug Treatments to Prevent Fragility Fractures: A Systematic Review and Network Meta-Analysis , 2012 .
[14] A. Soumilas,et al. A randomized trial comparing adjuvant fluorouracil, epirubicin, and mitomycin with no treatment in operable gastric cancer. , 1996, Chemotherapy.
[15] Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992, The Lancet.
[16] D. Altman,et al. Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research , 2004, Canadian Medical Association Journal.
[17] Richard Horton,et al. Putting clinical trials into context , 2005, The Lancet.
[18] Lin Feng. Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer , 2008 .
[19] A D Oxman,et al. Systematic Reviews: Checklists for review articles , 1994, BMJ.
[20] M. Parmar,et al. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.
[21] S. Barni,et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] Kristian Thorlund,et al. How to use an article reporting a multiple treatment comparison meta-analysis. , 2012, JAMA.
[23] D. Richards. The quality of systematic reviews in dentistry , 2004, Evidence-Based Dentistry.
[24] Anthony Delaney,et al. A systematic evaluation of the quality of meta-analyses in the critical care literature , 2005, Critical care.
[25] E. Romagnoli,et al. Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study , 2006, BMJ : British Medical Journal.
[26] C. Pera,et al. Positive results of adjuvant mitomycin-C in resected gastric cancer: a randomised trial on 134 patients. , 1993, European journal of cancer.
[27] V. Gebski,et al. AUSTRALASIAN GASTRO-INTESTINAL TRIALS GROUP. SURVIVAL BENEFI TS FROM NEOADJUVANT CHEMORADIOTHERAPY OR CHEMOTHERAPY IN OESOPHAGEAL CARCINOMA: A META-ANALYSIS , 2007 .
[28] Douglas G Altman,et al. Systematic reviews of evaluations of prognostic variables , 2001, BMJ : British Medical Journal.
[29] Kay Dickersin,et al. Publication Bias: Recognizing the Problem, Understanding Its Origins and Scope, and Preventing Harm , 2006 .
[30] Val Gebski,et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. , 2007, The Lancet. Oncology.
[31] I. Olkin,et al. The case of the misleading funnel plot , 2006, BMJ : British Medical Journal.
[32] Denis Xavier,et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial , 2008, The Lancet.
[33] Gordon H Guyatt,et al. GRADE guidelines: 9. Rating up the quality of evidence. , 2011, Journal of clinical epidemiology.
[34] Aller,et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. , 2002, The New England journal of medicine.
[35] Gerald Gartlehner,et al. [GRADE guidelines: 8. Rating the quality of evidence - indirectness]. , 2012, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.
[36] R. Simes,et al. Publication bias: evidence of delayed publication in a cohort study of clinical research projects , 1997, BMJ.
[37] S. Sheen-Chen,et al. Adjuvant chemotherapy for resectable gastric cancer: A preliminary report , 1994, Journal of surgical oncology.
[38] A. Nashimoto,et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial , 1999, The Lancet.
[39] W. G. Cochran. The combination of estimates from different experiments. , 1954 .
[40] G. Bonfanti. Adjuvant treatments following curative resection for gastric cancer , 1988, The British journal of surgery.
[41] E. Akl,et al. Randomisation to protect against selection bias in healthcare trials. , 2011, The Cochrane database of systematic reviews.
[42] W. Allum,et al. ADJUVANT CHEMOTHERAPY IN OPERABLE GASTRIC CANCER 5 Year Follow-up of First British Stomach Cancer Group Trial , 1989, The Lancet.
[43] J. Ioannidis,et al. Replication validity of genetic association studies , 2001, Nature Genetics.
[44] P. Lavin,et al. Postoperative adjuvant 5‐fluorouracil plus methyl‐CCNU therapy for gastric cancer patients. Eastern cooperative oncology group study (EST 3275) , 1985, Cancer.
[45] F. McAlister,et al. Acetylcysteine in the prevention of contrast-induced nephropathy: a case study of the pitfalls in the evolution of evidence. , 2006, Archives of internal medicine.
[46] Michael K Gould,et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. , 2006, American journal of respiratory and critical care medicine.
[47] M. Egger,et al. The hazards of scoring the quality of clinical trials for meta-analysis. , 1999, JAMA.
[48] Jeroen J. Bax,et al. The Effect of Bisoprolol on Perioperative Mortality and Myocardial Infarction in High-Risk Patients Undergoing Vascular Surgery , 2000 .
[49] S. Pocock,et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration , 2007, Epidemiology.
[50] Jonathan J Deeks,et al. Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests. , 2001, BMJ.
[51] P. Easterbrook,et al. Publication bias in clinical research , 1991, The Lancet.
[52] A. Jadad,et al. Examining the Evidence in Anesthesia Literature: A Critical Appraisal of Systematic Reviews , 2001, Anesthesia and analgesia.
[53] Mayo,et al. Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer , 1982, Cancer.
[54] M. Bhandari,et al. Meta-Analyses in Orthopaedic Surgery: A Systematic Review of Their Methodologies , 2001, The Journal of bone and joint surgery. American volume.
[55] D. Cook,et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? , 1998, The Lancet.
[56] I. Tusquets,et al. Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] S. Romano,et al. Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study. , 1996, British Journal of Cancer.
[58] Richard Smith,et al. Time to register randomised trials , 1999, BMJ.
[59] H. Wieand,et al. A prospective, randomized evaluation of intensive‐course 5‐fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer , 1991, Cancer.
[60] G. Guyatt,et al. Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.
[61] J. Crowley,et al. Vitamin E and the Risk of Prostate Cancer The Selenium and Vitamin E Cancer Prevention Trial ( SELECT ) , 2011 .
[62] A. Nashimoto,et al. Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] Scott A. Hundahl,et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. , 2001, The New England journal of medicine.
[64] A. Biondi,et al. Preoperative treatment and surgery in gastric cancer: friends or foes? , 2009, The Lancet. Oncology.
[65] Gordon Guyatt,et al. Tips for learners of evidence-based medicine: 4. Assessing heterogeneity of primary studies in systematic reviews and whether to combine their results , 2005, Canadian Medical Association Journal.
[66] B. Glimelius,et al. Chemotherapy in gastric cancer: a review and updated meta-analysis , 2002 .
[67] V. Sharma,et al. Metaanalysis of randomized controlled trials of endoscopic retrograde cholangiography and endoscopic sphincterotomy for the treatment of acute biliary pancreatitis , 1999, American Journal of Gastroenterology.
[68] D. Moher,et al. The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration , 2001, Annals of Internal Medicine.
[69] A. Hrõbjartsson,et al. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. , 2004, JAMA.
[70] Howard Balshem,et al. GRADE guidelines: 3. Rating the quality of evidence. , 2011, Journal of clinical epidemiology.
[71] G H Guyatt,et al. Users' guides to the medical literature. VI. How to use an overview. Evidence-Based Medicine Working Group. , 1994, JAMA.
[72] M. Zembala,et al. Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer , 2004, Gastric Cancer.
[73] G. Guyatt,et al. Individuals with diabetes preferred that future trials use patient-important outcomes and provide pragmatic inferences. , 2011, Journal of clinical epidemiology.
[74] J. Boissel,et al. Clinical trial registries and ethics review boards: the results of a survey by the FICHTRE project , 1997, Fundamental & clinical pharmacology.
[75] J. Pignon,et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial , 2007 .
[76] J. Ioannidis,et al. Quantitative Synthesis in Systematic Reviews , 1997, Annals of Internal Medicine.
[77] C. Mulrow. The medical review article: state of the science. , 1987, Annals of internal medicine.
[78] G. Guyatt,et al. GRADE guidelines 6. Rating the quality of evidence--imprecision. , 2011, Journal of clinical epidemiology.
[79] J. Sterne,et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.
[80] Jeroen J. Bax,et al. Bisoprolol and Fluvastatin for the Reduction of Perioperative Cardiac Mortality and Myocardial Infarction in Intermediate-Risk Patients Undergoing Noncardiovascular Surgery: A Randomized Controlled Trial (DECREASE-IV) , 2009, Annals of surgery.
[81] Mike Clarke,et al. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992 .
[82] P. Grambsch,et al. Proportional hazards tests and diagnostics based on weighted residuals , 1994 .
[83] Gerald Gartlehner,et al. [GRADE guidelines: 5. Rating the quality of evidence: publication bias]. , 2012, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.
[84] Y. Lacasse,et al. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. A Cochrane systematic review. , 2007, Europa medicophysica.
[85] R. Labianca,et al. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[86] J. Pignon,et al. Meta-analyses of randomised clinical trials in oncology. , 2001, The Lancet. Oncology.
[87] J. Manson,et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. , 2008, JAMA.
[88] E. Livingston,et al. Effect size estimation: a necessary component of statistical analysis. , 2009, Archives of surgery.
[89] L. Stewart,et al. Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group. , 1995, Statistics in medicine.
[90] T. Fleming,et al. Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A southwest oncology group study , 1995, Annals of Surgical Oncology.
[91] M. Clarke,et al. Handsearching versus electronic searching to identify reports of randomized trials. , 2002, The Cochrane database of systematic reviews.
[92] W. Allum,et al. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up , 1994, The Lancet.
[93] L. Mariani,et al. Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[94] Alessandro Liberati,et al. Assessment of methodological quality of primary studies by systematic reviews: results of the metaquality cross sectional study , 2005, BMJ : British Medical Journal.
[95] J. Sterne,et al. How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study. , 2003, Health technology assessment.
[96] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[97] Y. Kodera,et al. Efficacy of Adjuvant Chemotherapy Using Oral Fluorinated Pyrimidines for Curatively Resected Gastric Cancer: A Meta-Analysis of Centrally Randomized Controlled Clinical Trials in Japan , 2006, Journal of chemotherapy.
[98] Wu Ai-wen. Randomized Trial of Adjuvant Chemotherapy after Curative Resection for Gastric Cancer , 2005 .
[99] A. Neugut,et al. Epidemiology of gastric cancer. , 2006, World journal of gastroenterology.
[100] Jing-Yuan Fang,et al. The Role of Postoperative Adjuvant Chemotherapy Following Curative Resection for Gastric Cancer: A Meta-Analysis , 2008, Cancer investigation.
[101] Y. Ohashi,et al. Randomized controlled trial of adjuvant uracil–tegafur versus surgery alone for serosa‐negative, locally advanced gastric cancer , 2007, The British journal of surgery.
[102] Alexander Tsertsvadze,et al. Systematic reviews: when is an update an update? , 2006, The Lancet.
[103] G. Guyatt,et al. Estimating risk difference from relative association measures in meta-analysis can infrequently pose interpretational challenges. , 2009, Journal of clinical epidemiology.
[104] M. Fujii,et al. [The optimal period for orally administered fluoropyrimidines as an adjuvant chemotherapy for gastric cancer--a pilot study using 5-FU tablets compared with surgical operation alone]. , 1994, Gan to kagaku ryoho. Cancer & chemotherapy.
[105] Peter Fonagy,et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data , 2004, The Lancet.
[106] R. Labianca,et al. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. , 2008, Journal of the National Cancer Institute.
[107] Gerald Gartlehner,et al. [GRADE guidelines: 7. Rating the quality of evidence - inconsistency]. , 2012, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.
[108] Y. Wang,et al. An updated meta-analysis of adjuvant chemotherapy after curative resection for gastric cancer. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[109] J. Ioannidis,et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. , 2009, Journal of clinical epidemiology.
[110] B. Stewart,et al. World Cancer Report , 2003 .
[111] A. D. Schryver,et al. Systemic treatment of early breast-cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women: 1 , 1992 .
[112] David Moher,et al. Epidemiology and Reporting Characteristics of Systematic Reviews , 2007, PLoS medicine.
[113] Kay Dickersin,et al. The evolution of trial registries and their use to assess the clinical trial enterprise. , 2012, JAMA.
[114] John Hoey,et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. , 2004, JAMA.
[115] Yasuo Ohashi,et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. , 2007, The New England journal of medicine.
[116] M Schemper,et al. A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.
[117] A. Tres,et al. Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[118] M. Ychou,et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[119] G. Guyatt,et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.
[120] M. Schemper,et al. The effect of adjuvant chemotherapy in gastric carcinoma is dependent on tumor histology: 5-year results of a prospective randomized trial. , 1988, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[121] T. Nakajima,et al. Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[122] M. Huguier,et al. Gastric carcinoma treated by chemotherapy after resection: a controlled study. , 1980, American journal of surgery.
[123] N. Basso,et al. Randomized trial of adjuvant chemotherapy after curative resection for gastric cancer. , 2004, American journal of surgery.
[124] Grace Huang,et al. Aspirin as an Adjunct to Screening for Prevention of Sporadic Colorectal Cancer: A Cost-Effectiveness Analysis , 2001, Annals of Internal Medicine.
[125] I. Olkin,et al. Improving the quality of reports of meta‐analyses of randomised controlled trials: the QUOROM statement , 2000, Revista espanola de salud publica.
[126] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.
[127] D. Eyding,et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials , 2010, BMJ : British Medical Journal.